See Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.
http://www.ncbi.nlm....pubmed/23613267
See also
http://www.cmleukemi...ythemia-et.html